Gary Wertman, DO
Orthopaedic Surgery · Jacksonville, NCNPI 1083805006
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $554 of the $878 with a category attached, or 63.1%. 15 manufacturers reported payments, led by Arthrex at 45.3% of the total. Reporting peaked in 2022 at $430 and has fallen 96.5% since, to $15 in 2025. That places this record below the midpoint for orthopaedic surgery clinicians in NC, where the typical reported total is $4,547.
Across 27 payments — averaging $32.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$398
- Axogen$97
- Orthofix Medical, Inc.$93
- Smith+Nephew$50
- Stryker$34
- Endo USA, Inc.$34
- plus $173 from 9 others
What the payments were for
- Travel & lodging$32437%
- Food & beverage$55463%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 7 | $398 |
| Axogen | 1 | $97 |
| Orthofix Medical, Inc. | 5 | $93 |
| Smith+Nephew | 1 | $50 |
| Stryker | 1 | $34 |
| Endo USA, Inc. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Heron Therapeutics, Inc. | 1 | $24 |
| Fidia Pharma USA Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $17 |
| Zimmer Biomet | 1 | $16 |
| Avanos Medical | 1 | $15 |
| GSK | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
How this compares
$878 in reported general payments places this provider in the 20th percentile of 845 orthopaedic surgery providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 60 | $806 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 107 | $788 |
| Meloxicam | 194 | $377 |
| Cephalexin | 11 | $209 |
| Cyclobenzaprine Hcl | 45 | $204 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 37 | $203 |
| Gabapentin | 23 | $173 |
| Methylprednisolone | 22 | $111 |
| Tramadol Hcl | 48 | $63 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Jacksonville
- Thomas FehringCharlotte$18.3M
- Walter BeaverCharlotte$7.4M
- Robert AndersonCharlotte$6.6M
- William JiranekDurham$6.4M
- John MasonCharlotte$5.7M
- Thomas VailDurham$5.7M
- William DavisCharlotte$5.2M
- John EllingtonCharlotte$4.9M
- Mark EasleyDurham$4M
- Carroll JonesCharlotte$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.